Yu Zhang1,2, Fei Wang3, Hao-Ran Sun4, Ya-Kai Huang1,2, Jian-Peng Gao1,2, Hua Huang5,6. 1. Department of Gastric Surgery, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China. 2. Department of Oncology, Shanghai Medical College, Fudan University, 270 Dongan Road, Shanghai, 200032, People's Republic of China. 3. Department of Anesthesiology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China. 4. Department of General Surgery, Huashan Hospital, Fudan University, Shanghai, People's Republic of China. 5. Department of Gastric Surgery, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China. huahuang@fudan.edu.cn. 6. Department of Oncology, Shanghai Medical College, Fudan University, 270 Dongan Road, Shanghai, 200032, People's Republic of China. huahuang@fudan.edu.cn.
Abstract
PURPOSE: Apatinib, an antiangiogenic drug, has shown beneficial effects only in a fraction of advanced gastric cancer (GC) patients. Given the recent success of immunotherapies, combination of apatinib with immune checkpoint inhibitor may provide sustained and potent antitumor responses. METHODS: Immunocompetent mice with subcutaneous MFC tumors grown were given a combination of apatinib and anti-PD-L1 antibody therapy. GC tissues from patients undergoing curative resection in China were collected, and the density of HEVs, MSI status and tumor-infiltrated lymphocytes were analyzed by immunohistochemical staining. RESULTS: Combined apatinib and PD-L1 blockade therapy synergistically delayed tumor growth and increased survival in MFC-bearing immunocompetent mice. The combination therapy promoted antitumor immunity by increasing the ratio of CD8+ cytotoxic T cells to Foxp3+ Treg cells, the accumulation of CD20+ B cells and the Th1/Th2 cytokine ratio (IFN-γ/IL-10). The combination therapy induced the formation of HEVs through activation of LTβR signaling, thus promoting CD8+ cytotoxic T cell and CD20+ B cell infiltration in tumors. In clinical GC samples, the density of HEVs positively correlated with the intratumoral infiltration of CD8+ cytotoxic T cells and CD20+ B cells. MSI-high GC showed a higher density of HEVs, CD8+ cytotoxic T cells and CD20+ B cells than MSS/MSI-low GC. GC patients with high densities of HEVs, CD8+ cytotoxic T cells and CD20+ B cells had an improved prognosis with superior overall survival. CONCLUSION: Combining apatinib with PD-L1 blockade treatment synergistically enhances antitumor immune responses and promotes HEV formation in GC.
PURPOSE:Apatinib, an antiangiogenic drug, has shown beneficial effects only in a fraction of advanced gastric cancer (GC) patients. Given the recent success of immunotherapies, combination of apatinib with immune checkpoint inhibitor may provide sustained and potent antitumor responses. METHODS: Immunocompetent mice with subcutaneous MFC tumors grown were given a combination of apatinib and anti-PD-L1 antibody therapy. GC tissues from patients undergoing curative resection in China were collected, and the density of HEVs, MSI status and tumor-infiltrated lymphocytes were analyzed by immunohistochemical staining. RESULTS: Combined apatinib and PD-L1 blockade therapy synergistically delayed tumor growth and increased survival in MFC-bearing immunocompetent mice. The combination therapy promoted antitumor immunity by increasing the ratio of CD8+ cytotoxic T cells to Foxp3+ Treg cells, the accumulation of CD20+ B cells and the Th1/Th2 cytokine ratio (IFN-γ/IL-10). The combination therapy induced the formation of HEVs through activation of LTβR signaling, thus promoting CD8+ cytotoxic T cell and CD20+ B cell infiltration in tumors. In clinical GC samples, the density of HEVs positively correlated with the intratumoral infiltration of CD8+ cytotoxic T cells and CD20+ B cells. MSI-high GC showed a higher density of HEVs, CD8+ cytotoxic T cells and CD20+ B cells than MSS/MSI-low GC. GC patients with high densities of HEVs, CD8+ cytotoxic T cells and CD20+ B cells had an improved prognosis with superior overall survival. CONCLUSION: Combining apatinib with PD-L1 blockade treatment synergistically enhances antitumor immune responses and promotes HEV formation in GC.
Authors: Jennifer M Giltnane; Katherine E Hutchinson; Thomas P Stricker; Luigi Formisano; Christian D Young; Monica V Estrada; Mellissa J Nixon; Liping Du; Violeta Sanchez; Paula Gonzalez Ericsson; Maria G Kuba; Melinda E Sanders; Xinmeng J Mu; Eliezer M Van Allen; Nikhil Wagle; Ingrid A Mayer; Vandana Abramson; Henry Gόmez; Monica Rizzo; Weiyi Toy; Sarat Chandarlapaty; Erica L Mayer; Jason Christiansen; Danielle Murphy; Kerry Fitzgerald; Kai Wang; Jeffrey S Ross; Vincent A Miller; Phillip J Stephens; Roman Yelensky; Levi Garraway; Yu Shyr; Ingrid Meszoely; Justin M Balko; Carlos L Arteaga Journal: Sci Transl Med Date: 2017-08-09 Impact factor: 17.956
Authors: Rita Cabrita; Martin Lauss; Adriana Sanna; Marco Donia; Mathilde Skaarup Larsen; Shamik Mitra; Iva Johansson; Bengt Phung; Katja Harbst; Johan Vallon-Christersson; Alison van Schoiack; Kristina Lövgren; Sarah Warren; Karin Jirström; Håkan Olsson; Kristian Pietras; Christian Ingvar; Karolin Isaksson; Dirk Schadendorf; Henrik Schmidt; Lars Bastholt; Ana Carneiro; Jennifer A Wargo; Inge Marie Svane; Göran Jönsson Journal: Nature Date: 2020-01-15 Impact factor: 49.962
Authors: Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2018-09-12 Impact factor: 508.702